← boardnext 2026-09-11next 2030-03
ROIV
Urovant Sciences GmbHdistress 0/10 · well-funded / low risk$34.95+0%today-5% from 52w high
Lead: dermatomyositis
Revenue
pre-revenue
Liquidity
$4292M
Runway
5.1 yrs
Shares 1y
+5%
Price & events
+52.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.1%
1D
+3.0%
1W
+8.5%
1M
+24.2%
3M
+54.8%
6M
+206.8%
1Y
+217.4%
2Y
+252.7%
5Y
+243.7%
All
Overview
- Market Cap
- $25.14B
- Volume
- 288.94K
- 52 Week Range
- $11.17 – $36.81
- Total Shares
- 719.27M
- Float Shares
- 563.99M
- Short %
- 6.09%
- % Held by Insiders
- 23.39%
- % Held by Institutions
- 76.19%
- RVOL
- 0.05x
- Beta
- 1.11
Pipeline stages · 2 programs
Oral Brepocitinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Vibegron
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09-11 Estimated 50% readout ~2026-11-25 | Phase 3 | Brepocitinib PO QDpriority review | Uveitis, Posterior, Uveitis, Intermediate, Uveitis | — | active not recruiting |
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | Oral Brepocitinibpriority review | Cutaneous Sarcoidosis | — | recruiting |
| 2028-12-31 Estimated 50% readout ~2029-03-16 | Phase 2/3 | Oral Brepocitinibpriority review | Lichen Planopilaris | — | recruiting |
| 2030-03 Estimated 50% readout ~2030-05-15 | Phase 2/3 | Vibegron | Neurogenic Detrusor Overactivity | — | recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 21
- 2027Guided 40%readoutIMVT-1402 · Topline readouts from two registrational trials expected in 2027.SEC 8-K
- second half of calendar year 2026Guided 55%readoutPhase 2mosliciguat · Topline data expected H2 2026SEC 8-K
- calendar year 2026Guided 40%readoutIMVT-1402 · Topline data expected CY2026SEC 8-K
- second half of calendar year 2026Guided 55%readoutPhase 3brepocitinib · Topline data expected H2 2026SEC 8-K
- second half of calendar year 2026Guided 55%trial initiationsecondaryPhase 3brepocitinib · Phase 3 study initiation in CSSEC 8-K
- third quarter of calendar year 2026Guided 70%PDUFAPDUFAbrepocitinib · PDUFA target action date for brepocitinib NDASEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- calendar 1H 2026regulatory submissionFiled (NDA/BLA)brepocitinib · NDA filing planned for first half of 2026SEC 8-K
- first half of calendar year 2026readoutbrepocitinib · Topline data expected H1 2026SEC 8-K
- early calendar year 2026regulatory submissionFiled (NDA/BLA)brepocitinib · NDA filing expected early CY2026SEC 8-K
- 2026-03-03partnershipSpikevax · Global settlement of LNP patent infringement litigation between Genevant/Arbutus and Moderna, including $950M noncontingent payment due by July 8, 2026 and up to $1.3B contingent on Section 1498 appeal outcome.SEC 8-K
- summer 2025trial initiationsecondaryIMVT-1402 · Potentially registrational program expected to initiate in summer 2025SEC 8-K
- September 11, 2025 at ATA meetingconferencedata presentationsecondarybatoclimab · Six-month off-treatment remission data presented at ATA.SEC 8-K
- 2025-04-21trial initiationsecondaryIMVT-1402 · Proof-of-concept study initiated in CLESEC 8-K
- March 19, 2025 at 8:00 a.m. EDTconferencedata presentationsecondaryInvestor call to discuss MG and CIDP resultsSEC 8-K
- by calendar year endtrial initiationsecondaryPhase 3IMVT-1402 · Initiation of pivotal trial in Graves' Disease.SEC 8-K
- fourth quarter of calendar year 2024PDUFAPDUFAVTAMA (tapinarof) cream, 1% · FDA PDUFA action on sNDA for VTAMA in atopic dermatitis.SEC 8-K
- fourth quarter of calendar year 2024PDUFAPDUFAVTAMA · PDUFA for sNDA for VTAMA cream in atopic dermatitisSEC 8-K
- 2024-12-03trial discontinuednamilumab · Further development of namilumab for sarcoidosis discontinuedSEC 8-K
- 2024-10-28partnershipVTAMA (tapinarof) cream, 1% · Organon completed acquisition of Dermavant from Roivant.SEC 8-K
- 2024-09-18partnershipVTAMA · Organon to acquire Dermavant including VTAMA creamSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $39 (+12% upside) · 11 analysts
- 2026-05-26GuggenheimBuy
- 2026-05-21TD CowenBuy
- 2026-05-21CitigroupBuy
- 2026-05-21HC Wainwright & Co.Buy
- 2026-04-16Piper SandlerOverweight
- 2026-03-04HC Wainwright & Co.Buy
Competitors — dermatomyositis
Recent news
- 2026-07-22Form 4 Roivant Sciences Ltd. For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-22Form 4 Roivant Sciences Ltd. For: 21 July - Investing.com India
- 2026-07-22Roivant Sciences (ROIV) grants director Oren Ilan 775 fully vested shares - Stock Titan
- 2026-07-22Roivant Sciences (ROIV) director awarded 405 fully vested shares - Stock Titan
- 2026-07-22Roivant Sciences (ROIV) director granted 543 fully vested common shares - Stock Titan
- 2026-07-21Responsive Playbooks and the ROIV Inflection - Stock Traders Daily
- 2026-07-17Enjoin Reports 923% Average ROI Delivered in Q1 2026 - GlobeNewswire
- 2026-07-13Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring the 9.47% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.